Physician profile
Robert C Reams
NPI 1982044491
$7,485.04
in general payments reported to CMS, 2019-2025
10 companies · $3,717 in 2025
The $3,717 reported for 2025 was more than what 79% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $351 · 2020: $1,202 · 2021: $106 · 2022: $467 · 2023: $1,479 · 2024: $164 · 2025: $3,717.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,125 · Food and Beverage: $1,653 · Travel and Lodging: $1,582.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,125.00 |
| Food and Beverage | $1,653.19 |
| Travel and Lodging | $1,581.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $3,014.27 | 2020-2025 | |
| Linkbio Corp | $2,125.00 | 2025 | |
| Exactech, INC. | $617.05 | 2019-2023 | |
| Titan Surgical Group, LLC | $558.91 | 2020-2025 | |
| Stryker Corporation | $543.68 | 2019-2025 | Tornier Perform Reversed Augmented Glenoid, Inspace, Alphavent |
| Smith+Nephew, INC. | $249.46 | 2021-2022 | |
| Linvatec Corporation | $174.97 | 2023 | Biobrace 23mm |
| Anika Therapeutics, INC. | $147.37 | 2023 | Tactoset, X-Twist |
| Novartis Pharmaceuticals Corporation | $42.25 | 2022 | |
| Pacira Therapeutics, INC. | $12.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.